Lantern Pharma’s Proprietary A.I. Platform for Precision Oncology Drug Development, RADR®, Surpasses 10 Billion Datapoints – Significantly Enhancing Precision Medicine Capabilities & Expanding Potential for Biopharma Collaborations and Partnerships

- Represents a 10-fold increase in the number of datapoints from one year ago, November 2020, and a 37-fold increase since the June 2020 IPO - Accelerates the discovery of new indications for Lantern's existing drug candidates, as well as the identification of new drug candidates and combination therapies - Data growth was largest in bladder, pancreatic, brain and blood cancers